Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

ClinicalTrials.gov ID: NCT00398879

Public ClinicalTrials.gov record NCT00398879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal cancer which would be randomized to either capecitabine plus perifosine or capecitabine alone. The effects of perifosine may be manifested by increased time to progression, tumor regression reflected in partial or complete responses, or a combination of these outcomes. The primary goal of this trial is to obtain a preliminary and objective assessment of the effects of perifosine on time to progression.

Study identification

NCT ID
NCT00398879
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AEterna Zentaris
Industry
Enrollment
381 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2005
Primary completion
Nov 30, 2010
Completion
Sep 30, 2011
Last update posted
Mar 13, 2018

2005 – 2011

United States locations

U.S. sites
49
U.S. states
22
U.S. cities
48
Facility City State ZIP Site status
AOI Pharmaceuticals Investigative Site Tucson Arizona 85704
AOI Pharmaceuticals Investigative Site Beverly Hills California 90211
AOI Pharmaceuticals Investigative Site Deer Park California 94574
AOI Pharmaceuticals Investigative Site Monterey California 93940
AOI Pharmaceuticals Investigative Site Newport Beach California 92663
AOI Pharmaceuticals Investigative Site Pomona California 91767
AOI Pharmaceuticals Investigative Site Santa Rosa California 95403
AOI Pharmaceuticals Investigative Site Soquel California 95703
AOI Pharmaceuticals Investigative Site Stockton California 95207
AOI Pharmaceuticals Investigative Site Colorado Springs Colorado 80909
AOI Pharmaceuticals Investigative Site Greeley Colorado 80631
AOI Pharmaceuticals Investigative Site Middletown Connecticut 06457
AOI Pharmaceuticals Investigative Site Norwich Connecticut 06360
AOI Pharmaceuticals Investigative Site Aventura Florida 33180
AOI Pharmaceuticals Investigative Site Coral Springs Florida 33065
AOI Pharmaceuticals Investigative Site Lake City Florida 32055
AOI Pharmaceuticals Investigative Site Miami Florida 33176
AOI Pharmaceuticals Investigative Site Ormond Beach Florida 32174
AOI Pharmaceuticals Investigative Site Sebastian Florida 32958
AOI Pharmaceuticals Investigative Site Vero Beach Florida 32960
AOI Pharmaceuticals Investigative Site Augusta Georgia 30904
AOI Pharmaceuticals Investigative Site Lawrenceville Georgia 30045
AOI Pharmaceuticals Investigative Site Marietta Georgia 30060
AOI Pharmaceuticals Investigative Site Galesburg Illinois 61401
AOI Pharmaceuticals Investigative Site Park Ridge Illinois 60068
AOI Pharmaceuticals Investigative Site Louisville Kentucky 40202
AOI Pharmaceuticals Investigative Site Lafayette Louisiana 70506
AOI Pharmaceuticals Investigative Site Grand Rapids Michigan 49546
AOI Pharmaceuticals Investigative Site Kalamazoo Michigan 49048
AOI Pharmaceuticals Investigative Site Branson Missouri 65616
AOI Pharmaceuticals Investigative Site Billings Montana 59103
AOI Pharmaceuticals Investigative Site Great Falls Montana 59405
AOI Pharmaceuticals Investigative Site Albany New York 12208
AOI Pharmaceuticals Investigative Site Armonk New York 10504
AOI Pharmaceuticals Investigative Site Great Neck New York 11042
AOI Pharmaceuticals Investigative Site Wilmington North Carolina 28401
AOI Pharmaceuticals Investigative Site Dayton Ohio 45409
AOI Pharmaceuticals Investigative Site Pottsville Pennsylvania 17901
AOI Pharmaceuticals Investigative Site Sayre Pennsylvania 18840
AOI Pharmaceuticals Investigative Site Greenville South Carolina 29605
AOI Pharmaceuticals Investigative Site Chattanooga Tennessee 37404
AOI Pharmaceuticals Investigative Site Memphis Tennessee 38120
AOI Pharmaceuticals Investigative Site Dallas Texas 75231
AOI Pharmaceuticals Investigative Site Dallas Texas 75246
AOI Pharmaceuticals Investigative Site Tyler Texas 75702
AOI Pharmaceuticals Investigative Site Chesapeake Virginia 23320
AOI Pharmaceuticals Investigative Site Norfolk Virginia 23502
AOI Pharmaceuticals Investigative Site Spokane Washington 99218
AOI Pharmaceuticals Investigative Site Appleton Wisconsin 54915

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00398879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00398879 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →